Last reviewed · How we verify

intravesical instillation with HA-CS

University Hospital, Basel, Switzerland · FDA-approved active Small molecule

Intravesical instillation of hyaluronic acid and chondroitin sulfate creates a protective coating on the bladder urothelium to reduce irritation and inflammation.

Intravesical instillation of hyaluronic acid and chondroitin sulfate creates a protective coating on the bladder urothelium to reduce irritation and inflammation. Used for Interstitial cystitis / bladder pain syndrome, Recurrent urinary tract infections with bladder irritation.

At a glance

Generic nameintravesical instillation with HA-CS
SponsorUniversity Hospital, Basel, Switzerland
Drug classBladder protectant / Glycosaminoglycan replacement
ModalitySmall molecule
Therapeutic areaUrology
PhaseFDA-approved

Mechanism of action

HA-CS (hyaluronic acid-chondroitin sulfate) is a topical bladder coating agent that adheres to the damaged urothelial surface, forming a glycosaminoglycan layer that protects against irritants and reduces inflammatory responses. This mechanism helps restore the bladder's natural protective barrier function, particularly in conditions characterized by urothelial damage and chronic inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: